PCI – 7th June 2024
Thermofisher: Thu 29 February 2024, 11:15

Current Edition

Upcoming Events

Scientific Lab Show
SLAS
Bio IT
PEGS Boston
ELRIG Drug Discovery USA
Biotechnology Show 13.02.26
PFS & Injectable drug devices west coast
PFS & Injectable Drug Devices East Cost
Bio Trinity
Anglo Nordic

Advertisement

A&M Stabtest April 26
CDD Vault – 18.03.2025
Biopharma Group – 19th March 2025
QMB Innovation Centre
Polypure hompage

Optimisation of a Quality Control Method for Identity, Purity and Quantity for Oligonucleotide Therapeutics

Thomas Franz, Steven A. Watt, Rita Beel, Lejon Martens

Full-length messenger ribonucleic acid (mRNA) based vaccines came into fame in the aftermath of the 2019 coronavirus outbreak, which has rapidly developed into a global pandemic. The two mRNA vaccines developed by Moderna and BioNTech/ Pfizer were the first mRNA therapeutics to be granted an Emergency Use Authorization by the EMA and US-FDA and proved to be safe and efficacious treatments against COVID infection. In this application note, A&M STABTEST wants to present an LC MS-based platform method for the determination of the identity, purity and quantity of oligonucleotides and which parameters are worth investigating to optimise the method in terms of chromatographic resolution of impurities.

The Bridge 28.01
Newcells 3 June 2024, 15:12
Richter: Wed 23 October 2024, 09:03
Asychem – 10.04.2025
Taconic Biosciences – 29.04.25
Steribar – 12.05.2025
Crown Bioscience 08.09.2025
Aseptic Tech